<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/25/sutro-biopharma-inc-nasdaqstro-receives-consensus-rating-of-buy-from-analysts.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-25T10:30:42+00:00"/>
    <meta property="og:title" content="Sutro Biopharma Inc (NASDAQ:STRO) Receives Consensus Rating of “Buy” from Analysts"/>
    <meta property="og:description" content="Shares of Sutro Biopharma Inc (NASDAQ:STRO) have been assigned a consensus recommendation of “Buy” from the eight analysts that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have issued a buy recommendation on the company. The average […]"/>
  </head>
  <body>
    <article>
      <h1>Sutro Biopharma Inc (NASDAQ:STRO) Receives Consensus Rating of “Buy” from Analysts</h1>
      <address><time datetime="2019-11-25T10:30:42+00:00">25 Nov 2019, 10:30</time> by <a rel="author" href="https://www.thecerbatgem.com/author/scott" target="_blank">Scott Moore</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/sutro-biopharma-inc-logo.png"/>
      </figure>
      <p>Shares of Sutro Biopharma Inc (NASDAQ:STRO) have been assigned a consensus recommendation of “Buy” from the eight analysts that are currently covering the firm, <a href="https://www.marketbeat.com/">Marketbeat</a> reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $18.75.</p>
      <p>Several equities research analysts recently weighed in on the stock. BTIG Research assumed coverage on shares of Sutro Biopharma in a research note on Monday, October 7th. They issued a “buy” rating and a $19.00 target price for the company. <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=STRO">ValuEngine</a> cut shares of Sutro Biopharma from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Wedbush reiterated an “outperform” rating on shares of Sutro Biopharma in a research note on Wednesday, October 30th. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Sutro Biopharma in a research note on Monday, October 21st. Finally, <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> cut shares of Sutro Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, August 17th.</p>
      <p><a href="https://www.marketbeat.com/stocks/NASDAQ/STRO/price-target/">STRO stock</a> traded down $0.05 during mid-day trading on Wednesday, reaching $10.46. 54,700 shares of the stock traded hands, compared to its average volume of 26,673. Sutro Biopharma has a 52 week low of $7.69 and a 52 week high of $12.49. The business has a 50-day moving average of $10.10 and a two-hundred day moving average of $10.40. The firm has a market capitalization of $242.68 million, a PE ratio of -1.71 and a beta of 1.05.</p>
      <p>Sutro Biopharma (NASDAQ:STRO) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.65) by $0.09. The firm had revenue of $12.28 million for the quarter, compared to the consensus estimate of $8.88 million. Sell-side analysts predict that Sutro Biopharma will post -2.49 EPS for the current fiscal year.</p>
      <p>Several hedge funds and other institutional investors have recently added to or reduced their stakes in STRO. Acadian Asset Management LLC lifted its stake in Sutro Biopharma by 1,365.7% during the second quarter. Acadian Asset Management LLC now owns 9,058 shares of the company’s stock worth $103,000 after purchasing an additional 8,440 shares during the period. Wells Fargo &amp; Company MN lifted its stake in Sutro Biopharma by 240.7% during the second quarter. Wells Fargo &amp; Company MN now owns 11,484 shares of the company’s stock worth $130,000 after purchasing an additional 8,113 shares during the period. Rhumbline Advisers lifted its stake in Sutro Biopharma by 9.3% during the third quarter. Rhumbline Advisers now owns 13,578 shares of the company’s stock worth $123,000 after purchasing an additional 1,156 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Sutro Biopharma by 72.3% during the second quarter. Charles Schwab Investment Management Inc. now owns 22,592 shares of the company’s stock worth $258,000 after purchasing an additional 9,482 shares during the period. Finally, Bank of New York Mellon Corp lifted its stake in Sutro Biopharma by 104.8% during the second quarter. Bank of New York Mellon Corp now owns 30,472 shares of the company’s stock worth $347,000 after purchasing an additional 15,591 shares during the period. Institutional investors and hedge funds own 51.63% of the company’s stock.</p>
      <p>
        <b>Sutro Biopharma Company Profile</b>
      </p>
      <p>Sutro Biopharma, Inc operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers.</p>
      <p>See Also: <a href="https://www.marketbeat.com/financial-terms/risk-of-owning-bonds/">The risks of owning bonds</a></p>
      <figure>
        <img src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=STRO"/>
      </figure>
    </article>
  </body>
</html>